全结肠系膜切除术治疗结肠癌的临床疗效与安全性评价

doi:10.3877/cma.j.issn.1674-0793.2020.02.019

目的

系统评价结肠癌患者行全结肠系膜切除术（CME）的手术安全性、手术标本质量和远期预后效果。

方法

计算机检索PubMed、ScienceDirect、Cochrane、Scopus、中国知网和万方数据库中发表的相关文献，时间从建库至2018年12月。提取手术安全性、手术标本质量和远期生存率研究结果。

结果

共纳入15项研究8 914例患者。与传统非全结肠系膜切除术（NCME）组相比，CME组术后并发症明显增多（RR=1.23，95% CI：1.08~1.40），清扫的淋巴结数目更多（WMD=8.42，95% CI：4.71~12.13），肿瘤至血管高位结扎处的距离更长（WMD=18.43，95% CI：16.18~20.69），切除肠系膜的面积更大（WMD=35.07，95% CI：12.78~57.36），患者3年生存率（HR=0.72，95% CI：0.61~0.86）和5年生存率（HR=0.55，95% CI：0.42~0.73）更高（均P<0.01）。

结论

CME可以有效改善手术标本质量，延长术后远期生存率，但手术并发症的发生率较高，手术安全性问题应引起注意。

关键词: 结肠肿瘤, 结肠切除术, Meta分析, 全结肠系膜切除术

Objective

To evaluate the safety, sample quality and long-term prognosis of complete mesocolic excision (CME) for colorectal cancer.

Methods

The relevant documents published in PubMed, ScienceDirect, Cochrane, Scopus, CNKI and Wanfang databases were searched by computer from the establishment of the database to December 2018. The results of safety, quality and long-term survival were extracted.

Results

A total of 8 914 patients from 15 studies were included in this Meta-analysis. Compared with non-complete mesocolic excision (NCME) group, CME group had more complications (RR=1.23, 95% CI: 1.08-1.40), more lymph nodes (WMD=8.42, 95% CI: 4.71-12.13), longer distance from tumor to high ligation of blood vessels (WMD=18.43, 95% CI: 16.18-20.69), larger area of mesentery (WMD=35.07, 95% CI: 12.78-57.36). The 3-, 5- year survival rates of the patients in CME group were both higher (HR=0.72, 95% CI: 0.61-0.86; HR=0.55, 95% CI: 0.42-0.73; both P<0.01).

Conclusion

CME can effectively improve the quality of surgical specimens and prolong the long-term survival rate, but the incidence of surgical complications is high, so the safety of operation should be concerned.

Key words: Colonic neoplasms, Colectomy, Meta-analysis, Complete mesocolic excision

表1 纳入研究信息汇总（CME/NCME）

纳入研究(发表年)	研究时间(年)	国家	MINORS评分	分期^a	病例量(例)^b	年龄(岁) ^b	性别(%)^b,c	右半结肠癌占比(%)^b
West (2010)^[11]	1999—2008	德国	11	Ⅰ~Ⅳ	49/40	-	49/48	61/40
West (2010)^[12]	2008—2009	丹麦	13	Ⅰ~Ⅳ	93/170	70/72	60/44	44/34
Bertelsen (2011)^[13]	2007—2009	丹麦	13	Ⅰ~Ⅳ	93/105	70/73	56/50	50/57
Galizia (2014)^[14]	2004—2012	意大利	14	A~D	45/58	67/68	49/57	100/100
Storli (2014)^[15]	2007—2008	挪威	15	Ⅰ~Ⅲ	84/105	73/73	52/51	45/44
Siani (2015)^[16]	2008—2013	意大利	11	Ⅰ~Ⅲ	75/40	-	-	100/100
Bernhoff (2015)^[17]	2001—2008	瑞典	13	Ⅰ~Ⅲ	684/625	75/75	40/45	100/100
Bertelsen (2015)^[18]	2008—2011	丹麦	12	Ⅰ~Ⅲ	364/1 031	72/73	52/46	46/44
Bertelsen (2016)^[19]	2008—2013	丹麦	13	Ⅰ~Ⅲ	529/1 701	72/73	51/47	47/46
Merkel (2016)^[20]	1978—2014	德国	14	Ⅰ~Ⅲ	1 099/920	66/65	59/52	31/17
Thorsen(2016)^[21]	2007—2014	挪威	14	-	49/49	67/65	39/41	100/100
Agalianos (2017)^[22]	2006—2011	希腊	14	Ⅰ~Ⅲ	145/145	68/72	61/54	29/40
Gao (2018)^[6]	2012—2016	中国	14	Ⅰ~Ⅲ	220/110	68/73	55/49	58/52
Gian (2018)^[23]	2001—2014	瑞士	14	Ⅰ~Ⅳ	71/84	74/74	55/50	85/82
Abdelkhalek (2018)^[7]	2010—2015	埃及	13	Ⅰ~Ⅳ	52/79	66/58	50/52	48/49

表1 纳入研究信息汇总（CME/NCME）

纳入研究(发表年)	研究时间(年)	国家	MINORS评分	分期^a	病例量(例)^b	年龄(岁) ^b	性别(%)^b,c	右半结肠癌占比(%)^b
West (2010)^[11]	1999—2008	德国	11	Ⅰ~Ⅳ	49/40	-	49/48	61/40
West (2010)^[12]	2008—2009	丹麦	13	Ⅰ~Ⅳ	93/170	70/72	60/44	44/34
Bertelsen (2011)^[13]	2007—2009	丹麦	13	Ⅰ~Ⅳ	93/105	70/73	56/50	50/57
Galizia (2014)^[14]	2004—2012	意大利	14	A~D	45/58	67/68	49/57	100/100
Storli (2014)^[15]	2007—2008	挪威	15	Ⅰ~Ⅲ	84/105	73/73	52/51	45/44
Siani (2015)^[16]	2008—2013	意大利	11	Ⅰ~Ⅲ	75/40	-	-	100/100
Bernhoff (2015)^[17]	2001—2008	瑞典	13	Ⅰ~Ⅲ	684/625	75/75	40/45	100/100
Bertelsen (2015)^[18]	2008—2011	丹麦	12	Ⅰ~Ⅲ	364/1 031	72/73	52/46	46/44
Bertelsen (2016)^[19]	2008—2013	丹麦	13	Ⅰ~Ⅲ	529/1 701	72/73	51/47	47/46
Merkel (2016)^[20]	1978—2014	德国	14	Ⅰ~Ⅲ	1 099/920	66/65	59/52	31/17
Thorsen(2016)^[21]	2007—2014	挪威	14	-	49/49	67/65	39/41	100/100
Agalianos (2017)^[22]	2006—2011	希腊	14	Ⅰ~Ⅲ	145/145	68/72	61/54	29/40
Gao (2018)^[6]	2012—2016	中国	14	Ⅰ~Ⅲ	220/110	68/73	55/49	58/52
Gian (2018)^[23]	2001—2014	瑞士	14	Ⅰ~Ⅳ	71/84	74/74	55/50	85/82
Abdelkhalek (2018)^[7]	2010—2015	埃及	13	Ⅰ~Ⅳ	52/79	66/58	50/52	48/49

图1 文献筛选流程图

表2 两种术式的手术安全性研究

纳入研究(发表年)	病例量(例)		手术时间(min) ^a		术中出血量(ml)^a		并发症［例(%)］		术后病死率［例(%)］
纳入研究(发表年)	CME	NCME	CME	NCME	CME	NCME	CME	NCME	CME	NCME
Gao (2018)^[6]	220	110	175±10	180±11	80±8	110±25	43(19.5)	14(12.7)	-	-
Abdelkhalek (2018)^[7]	52	79	135±8	180±18	105±5	200±25	2(3.8)	5(6.3)	-	-
Bertelsen (2011)^[13]	105	93	-	-	250±256	217±356	19(18.1)	14(15.1)	6(5.7)	8(8.6)
Galizia (2014)^[14]	45	58	178±21	130±20	280±40	200±30	6(13.3)	7(12.1)	-	-
Bertelsen (2016)^[19]	529	1 701	-	-	-	-	110(20.8)	329(19.3)	33(6.2)	83(4.9)
Merkel (2016)^[20]	1 099	920	-	-	-	-	234(21.3)	143(15.5)	30(2.7)	25(2.7)
Gian (2018)^[23]	71	84	174±48	155±52	100±127	300±658	-	-	5(7.0)	0(0)

表2 两种术式的手术安全性研究

纳入研究(发表年)	病例量(例)		手术时间(min) ^a		术中出血量(ml)^a		并发症［例(%)］		术后病死率［例(%)］
纳入研究(发表年)	CME	NCME	CME	NCME	CME	NCME	CME	NCME	CME	NCME
Gao (2018)^[6]	220	110	175±10	180±11	80±8	110±25	43(19.5)	14(12.7)	-	-
Abdelkhalek (2018)^[7]	52	79	135±8	180±18	105±5	200±25	2(3.8)	5(6.3)	-	-
Bertelsen (2011)^[13]	105	93	-	-	250±256	217±356	19(18.1)	14(15.1)	6(5.7)	8(8.6)
Galizia (2014)^[14]	45	58	178±21	130±20	280±40	200±30	6(13.3)	7(12.1)	-	-
Bertelsen (2016)^[19]	529	1 701	-	-	-	-	110(20.8)	329(19.3)	33(6.2)	83(4.9)
Merkel (2016)^[20]	1 099	920	-	-	-	-	234(21.3)	143(15.5)	30(2.7)	25(2.7)
Gian (2018)^[23]	71	84	174±48	155±52	100±127	300±658	-	-	5(7.0)	0(0)

图2 两种术式安全性比较的森林图　A为手术时间；B为术中出血量；C为手术并发症；D为术后病死率

表3 两种术式的手术标本质量研究

纳入研究(发表年)	病例量(例)		切除肠管的长度(mm)^a		肿瘤到血管高位结扎处的距离(mm) ^a		切除系膜面积(mm²)^a		清扫淋巴结总数(个)^a
纳入研究(发表年)	CME	NCME	CME	NCME	CME	NCME	CME	NCME	CME	NCME
Gao (2018)^[6]	220	110	208±11	212±13	144±26	121±28	131±8	91±6	24±3	20±2
Abdelkhalek (2018)^[7]	52	79	-	-	-	-	-	-	23±4	12±1
West (2010)^[11]	49	40	-	-	-	-	-	-	30±4	18±3
West (2010)^[12]	93	170	315±30	247±13	105±33	84±25	145±88	87±35	28±2	18±2
Bertelsen (2011)^[13]	92	80	-	-	96±34	71±22	-	-	27±1	25±1
Galizia (2014)^[14]	45	58	288±27	274±41	106±13	87±17	-	-	20±9	15±6
Storli (2014)^[15]	84	40	262±145	274±192	-	-	-	-	16±10	15±7
Siani (2015)^[16]	75	40	235±37	213±25	103±5	87±9	154±16	141±12	29±5	19±7
Bertelsen (2015)^[18]	364	1 031	-	-	-	-	-	-	36.5±15.9	20.9±10
Bertelsen (2016)^[19]	529	1 701	-	-	-	-	-	-	36±4	20±2
Thorsen (2016)^[21]	49	49	242±72	232±73	-	-	-	-	38±13	21±9
Gian (2018)^[23]	71	84	-	-	-	-	-	-	32±17	23±13

表3 两种术式的手术标本质量研究

纳入研究(发表年)	病例量(例)		切除肠管的长度(mm)^a		肿瘤到血管高位结扎处的距离(mm) ^a		切除系膜面积(mm²)^a		清扫淋巴结总数(个)^a
纳入研究(发表年)	CME	NCME	CME	NCME	CME	NCME	CME	NCME	CME	NCME
Gao (2018)^[6]	220	110	208±11	212±13	144±26	121±28	131±8	91±6	24±3	20±2
Abdelkhalek (2018)^[7]	52	79	-	-	-	-	-	-	23±4	12±1
West (2010)^[11]	49	40	-	-	-	-	-	-	30±4	18±3
West (2010)^[12]	93	170	315±30	247±13	105±33	84±25	145±88	87±35	28±2	18±2
Bertelsen (2011)^[13]	92	80	-	-	96±34	71±22	-	-	27±1	25±1
Galizia (2014)^[14]	45	58	288±27	274±41	106±13	87±17	-	-	20±9	15±6
Storli (2014)^[15]	84	40	262±145	274±192	-	-	-	-	16±10	15±7
Siani (2015)^[16]	75	40	235±37	213±25	103±5	87±9	154±16	141±12	29±5	19±7
Bertelsen (2015)^[18]	364	1 031	-	-	-	-	-	-	36.5±15.9	20.9±10
Bertelsen (2016)^[19]	529	1 701	-	-	-	-	-	-	36±4	20±2
Thorsen (2016)^[21]	49	49	242±72	232±73	-	-	-	-	38±13	21±9
Gian (2018)^[23]	71	84	-	-	-	-	-	-	32±17	23±13

图3 两种术式质量研究结果比较的森林图　A为切除肠管长度；B为清扫淋巴结数目；C为肿瘤到血管高位结扎处的距离；D为切除肠系膜的面积

表4 两种术式的手术预后比较

纳入研究(发表年)	病例数(例)		3年生存率(%)		HR(95% CI)	5年生存率(%)		HR(95% CI)
纳入研究(发表年)	CME	NCME	CME	NCME	HR(95% CI)	CME	NCME	HR(95% CI)
Galizia (2014)^[14]	45	58	94^a	84^a	0.97(0.11~8.86)	90^a	74^a	0.40(0.17~1.27)
Storli (2014)^[15]	84	105	88^b	79^b	0.36(0.14~0.72)	-	-	-
Bernhoff (2015)^[17]	684	625	72^c	65^c	0.79(0.64~0.97)	-	-	-
Bertelsen (2015)^[18]	364	1 031	87^c	80^c	0.64(0.47~0.88)	-	?	-
Merkel (2016)^[20]	429	414	-	-	-	91^a	79^a	0.54(0.38~0.77)
Agalianos (2017)^[22]	145	145	-	-	-	81^b	71^b	0.66(0.38~1.13)
Gao (2018)^[6]	218	107	98^b	97^b	0.67(0.16~2.87)	-	-	-

表4 两种术式的手术预后比较

纳入研究(发表年)	病例数(例)		3年生存率(%)		HR(95% CI)	5年生存率(%)		HR(95% CI)
纳入研究(发表年)	CME	NCME	CME	NCME	HR(95% CI)	CME	NCME	HR(95% CI)
Galizia (2014)^[14]	45	58	94^a	84^a	0.97(0.11~8.86)	90^a	74^a	0.40(0.17~1.27)
Storli (2014)^[15]	84	105	88^b	79^b	0.36(0.14~0.72)	-	-	-
Bernhoff (2015)^[17]	684	625	72^c	65^c	0.79(0.64~0.97)	-	-	-
Bertelsen (2015)^[18]	364	1 031	87^c	80^c	0.64(0.47~0.88)	-	?	-
Merkel (2016)^[20]	429	414	-	-	-	91^a	79^a	0.54(0.38~0.77)
Agalianos (2017)^[22]	145	145	-	-	-	81^b	71^b	0.66(0.38~1.13)
Gao (2018)^[6]	218	107	98^b	97^b	0.67(0.16~2.87)	-	-	-

图4 两种术式患者预后研究结果比较的森林图　A为3年生存率；B为5年生存率

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2]	Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer[J]. Lancet, 1986, 1(8496): 1479-1482.
[3]	Hohenberger W, Weber K, Matzel K, et al. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation-technical notes and outcome[J]. Colorectal Dis, 2009, 11(4): 354-364; discussion 364-365.
[4]	Wang C, Gao Z, Shen K, et al. Safety, quality and effect of complete mesocolic excision vs non-complete mesocolic excision in patients with colon cancer: A systemic review and Meta-analysis[J]. Colorectal Dis, 2017, 19(11): 962-972.
[5]	Alhassan N, Yang M, Wong-Chong N, et al. Comparison between conventional colectomy and complete mesocolic excision for colon cancer: A systematic review and pooled analysis: A review of CME versus conventional colectomies[J]. Surg Endosc, 2019, 33(1): 8-18.
[6]	Gao Z, Wang C, Cui Y, et al. Efficacy and safety of complete mesocolic excision in patients with colon cancer: three-year results from a prospective, nonrandomized, double-blind, controlled trial[J]. Ann Surg, 2020, 27(3): 519-526.
[7]	Abdelkhalek M, Setit A, Bianco F, et al. Complete mesocolic excision with central vascular ligation in comparison with conventional surgery for patients with colon cancer-the experiences at two centers[J]. Ann Coloproctol, 2018, 34(4): 180-186.
[8]	Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument[J]. ANZ J Surg, 2003, 73(9): 712-716.
[9]	Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample[J]. BMC Med Res Methodol, 2005, 5: 13.
[10]	Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into Meta-analysis[J]. Trials, 2007, 8: 16.
[11]	West NP, Hohenberger W, Weber K, et al. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon[J]. J Clin Oncol, 2010, 28(2): 272-278.
[12]	West NP, Sutton KM, Ingeholm P, et al. Improving the quality of colon cancer surgery through a surgical education program[J]. Dis Colon Rectum, 2010, 53(12): 1594-1603.
[13]	Bertelsen CA, Bols B, Ingeholm P, et al. Can the quality of colonic surgery be improved by standardization of surgical technique with complete mesocolic excision?[J]. Colorectal Dis, 2011, 13(10): 1123-1129.
[14]	Galizia G, Lieto E, De Vita F, et al. Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study[J]. Int J Colorectal Dis, 2014, 29(1): 89-97.
[15]	Storli KE, Søndenaa K, Furnes B, et al. Short term results of complete (D3) vs. standard (D2) mesenteric excision in colon cancer shows improved outcome of complete mesenteric excision in patients with TNM stages -[J]. Tech Coloproctol, 2014, 18(6): 557-564.
[16]	Siani LM, Pulica C. Laparoscopic complete mesocolic excision with central vascular ligation in right colon cancer: long-term oncologic outcome between mesocolic and non-mesocolic planes of surgery[J]. Scand J Surg, 2015, 104(4): 219-226.
[17]	Bernhoff R, Martling A, Sjövall A, et al. Improved survival after an educational project on colon cancer management in the county of Stockholm-a population based cohort study[J]. Eur J Surg Oncol, 2015, 41(11): 1479-1484.
[18]	Bertelsen CA, Neuenschwander AU, Jansen JE, et al. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: A retrospective, population-based study[J]. Lancet Oncol, 2015, 16(2): 161-168.
[19]	Bertelsen CA, Neuenschwander AU, Jansen JE, et al. Short-term outcomes after complete mesocolic excision compared with 'conventional’ colonic cancer surgery[J]. Br J Surg, 2016, 103(5): 581-589.
[20]	Merkel S, Weber K, Matzel KE, et al. Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision[J]. Br J Surg, 2016, 103(9): 1220-1229.
[21]	Thorsen Y, Stimec B, Andersen SN, et al. Bowel function and quality of life after superior mesenteric nerve plexus transection in right colectomy with D3 extended mesenterectomy[J]. Tech Coloproctol, 2016, 20(7): 445-453.
[22]	Agalianos C, Gouvas N, Dervenis C, et al. Is complete mesocolic excision oncologically superior to conventional surgery for colon cancer? A retrospective comparative study[J]. Ann Gastroenterol, 2017, 30(6): 688-696.
[23]	Prevost GA, Odermatt M, Furrer M, et al. Postoperative morbidity of complete mesocolic excision and central vascular ligation in right colectomy: A retrospective comparative cohort study[J]. World J Surg Oncol, 2018, 16(1): 214.
[24]	West NP, Morris EJ, Rotimi O, et al. Pathology grading of colon cancer surgical resection and its association with survival: A retrospective observational study[J]. Lancet Oncol, 2008, 9(9): 857-865.
[25]	Freund MR, Edden Y, Reissman P, et al. Iatrogenic superior mesenteric vein injury: the perils of high ligation[J]. Int J Colorectal Dis, 2016, 31(9): 1649-1651.
[26]	Elsaleh H, Iacopetta B. Re: Pooled analysis of fluorouracil-based adjuvant therapy of stage Ⅱ and Ⅲ colon cancer: who benefits and by how much?[J]. J Clin Oncol, 2005, 23(3): 653-654; author reply 654-655.
[27]	Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089[J]. J Clin Oncol, 2003, 21(15): 2912-2919.
[28]	Sjo OH, Merok MA, Svindland A, et al. Prognostic impact of lymph node harvest and lymph node ratio in patients with colon cancer[J]. Dis Colon Rectum, 2012, 55(3): 307-315.
[29]	Lu JY, Xu L, Xue HD, et al. The radical extent of lymp-hadenectomy-D2 dissection versus complete mesocolic excision of laparoscopic right colectomy for right-sided colon cancer (RELARC) trial: study protocol for a randomized controlled trial[J]. Trials, 2016, 17(1): 582.

[1]	蚁淳, 袁冬生, 熊学军. 系统免疫炎症指数与骨密度降低和骨质疏松的关联[J/OL]. 中华关节外科杂志(电子版), 2024, 18(05): 609-617.
[2]	崔宏帅, 冯丽明, 东维玲, 韩博. 腹腔镜右半结肠癌D3根治术+IGLN清扫术治疗局部进展期结肠肝曲癌的临床效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 566-569.
[3]	丁志翔, 于鹏, 段绍斌. 血浆BRAF基因检测对腹腔镜右半结肠癌D3根治术中行幽门淋巴结清扫的指导价值[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 570-573.
[4]	王维花, 王楠, 乔庆, 罗红. 完全腹腔镜右半结肠癌切除术两种腔内消化道重建方案对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 574-577.
[5]	李晓鸥, 杨鹤鸣, 王国栋, 林海冠, 杨建武. 不同入路腹腔镜左半结肠癌根治术治疗效果对比[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 377-380.
[6]	马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[7]	何慧玲, 鲁祖斌, 冯嘉莉, 梁声强. 术前外周血NLR和PLR对结肠癌术后肝转移的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 682-687.
[8]	龚财芳, 赵俊宇, 游川. 围手术期肠内营养在肝癌肝切除患者中有效性及安全性的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 551-556.
[9]	关国欣, 罗福文. 结肠癌合并急性梗阻的个性化处理[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 459-463.
[10]	石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[11]	任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[12]	王芳, 刘达, 左智炜, 盛金平, 陈庭进, 蒋锐. 定量CT与双能X线骨密度仪对骨质疏松诊断效能比较的Meta分析[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 363-371.
[13]	靳英, 付小霞, 陈美茹, 袁璐, 郝力瑶. CD147调控MAPK信号通路对结肠癌细胞增殖和凋亡的影响及机制研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 474-480.
[14]	周倩妹, 王宪娥, 徐筱, 老慧琳, 赵欣悦, 胡菁颖. 多元化系统护理对老年人群牙周健康指标影响的系统评价[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 500-506.
[15]	傅新露, 李之岳, 卢丹. 妊娠合并结肠癌穿孔致脓毒症休克一例并文献复习[J/OL]. 中华产科急救电子杂志, 2024, 13(04): 227-231.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical efficacy and safety of complete mesocolic excision in the treatment of colon cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical efficacy and safety of complete mesocolic excision in the treatment of colon cancer